Overall rank by patents
#28,337
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Cellomics, Inc.
USPTO PatentsView assignee record - 9 granted patents across 9 technology areas, active 2015–2019. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G02B (OPTICAL ELEMENTS, SYSTEMS OR APPARATUS).
9
Total patents granted
9
CPC technology areas
20.3
Avg claims per patent
-100%
5-year filing velocity
The verdict
Cellomics holds 9 US patents across 9 technology areas, rank #28,337 of 50,000 tracked assignees.
- #28,337
- of 50,000 US assignees by volume
- Top 65%
- by Innovation Score (30.8/100)
- 20.3
- avg claims per patent
- -100%
- filing velocity, last 5 yrs
Portfolio overview
Cellomics, Inc. has been granted 9 US utility patents between 2015 and 2019, placing Cellomics, Inc. at rank #28,337 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 20.3 claims per patent with primary concentration in G02B (OPTICAL ELEMENTS, SYSTEMS OR APPARATUS). As a US Corporation, Cellomics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Cellomics sits between CC Biotechnology Corporation (9 patents, rank #28,333) and Cemedine Co., Ltd. (9 patents, rank #28,341) - the closest US assignees by grant volume. The composite Innovation Score of 30.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 0 grants, compared with 9 in the 2015–2019 window, a -100% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Cellomics, Inc.'s 20.3 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Cellomics, Inc. against peers pursuing similar technology classes.
Who files at Cellomics's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- CC Biotechnology
CC BIOTECHNOLOGY CORPORATION
9 patents
- CCA and B
CCA and B, LLC
9 patents
- CCCC First Harbor…
CCCC FIRST HARBOR ENGINEERING CO., LTD.
9 patents
- CCS Contractor Eq…
CCS Contractor Equipment &SupplyLLC
9 patents
- Cellular Biomedic…
CELLULAR BIOMEDICINE GROUP HK LIMITED
9 patents
- Celon Pharma
CELON PHARMA S.A.
9 patents
- Celyad
CELYAD S.A.
9 patents
- Cemedine
CEMEDINE CO., LTD.
9 patents
- Cellomics ◀
CELLOMICS, INC.
9 patents
What this shows Cellomics holds 9 patents at rank #28,337, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Cellomics
By rank, the assignees closest to #28,337 in granted patent volume.
- CC Biotechnology Corporation #28,333 · 9 patents
- CCA And B, Llc #28,334 · 9 patents
- CCCC First Harbor Engineering Co., Ltd. #28,335 · 9 patents
- CCS Contractor Equipment &supplyllc #28,336 · 9 patents
- Cellular Biomedicine Group HK Limited #28,338 · 9 patents
- Celon Pharma S.a. #28,339 · 9 patents
- Celyad S.a. #28,340 · 9 patents
- Cemedine Co., Ltd. #28,341 · 9 patents
Leaders in G02B (Optical Elements)
Other assignees with the most granted patents in Cellomics's primary technology class.
- Samsung Electronics Co., Ltd. 4,608 in class
- Canon Kabushiki Kaisha 2,525 in class
- Fujifilm Corporation 2,173 in class
- BOE Technology Group Co., Ltd. 1,899 in class
- Olympus Corporation 1,893 in class
- SONY Group Corporation 1,572 in class
- Apple Inc. 1,367 in class
- Seiko Epson Corporation 1,332 in class
Cellomics's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
31 Top 65% higher than 35% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 3 | 33.3% |
| 2016 | 1 | 11.1% |
| 2017 | 1 | 11.1% |
| 2019 | 4 | 44.4% |
Which technologies does Cellomics, Inc. patent most?
Top 9 of 9 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Cellomics, Inc. hold?
Cellomics, Inc. holds 9 US granted patents filed between 2015 and 2019, spanning 9 technology areas.
What is Cellomics, Inc.'s Innovation Score?
Cellomics, Inc. has an Innovation Score of 30.8 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Cellomics, Inc. focus on?
Cellomics, Inc.'s top technology area is G02B (OPTICAL ELEMENTS, SYSTEMS OR APPARATUS) with 7 patents. The company has filed patents in 9 CPC subclasses total.
Is Cellomics, Inc.'s patent filing rate increasing or decreasing?
Cellomics, Inc.'s recent filing velocity is -100% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Cellomics, Inc.'s patents?
Cellomics, Inc.'s patents average 20.3 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Cellomics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Cellomics's 9 grants land it in the top 65% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Cellomics ranks #28,337 of 50,000. Top 50 holders
- Most of this portfolio concentrates in G02B - see who else leads that technology area. G02B leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.